Entresto, a New Panacea for Heart Failure?
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.org..
Heart Failure (HF) is one of the main healthcare burdens in the United States and in the world. Many drugs are approved and used in practice for management of this condition; including beta blockers, diuretics, aldosterone antagonists, Angiotensin Converting Enzyme Inhibitors (ACEI's), and Angiotensin Receptor Blockers (ARBs). Recently, the Food and Drug Administration (FDA) approved a drug with brand name Entresto (Sacubitril/Valsartan or LCZ696), an angiotensin receptor neprilysin inhibitor for the use in Heart Failure with Reduced Ejection Fraction (HFrEF) patients instead of ACEI's and ARBs. The drug works through angiotensin receptor blockage via valsartan as well as neprilysin inhibition with sacubitril. This represented a new milestone in managing heart failure patients and provided yet another therapy in our armamentarium. This article reviews the stages that led to the development of this drug, the failure of its preceding agents, the lessons we have learnt, and the current trials of Entresto for new indications.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Cardiovascular & hematological agents in medicinal chemistry - 16(2018), 1 vom: 01., Seite 5-11 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Khalil, Peter [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.02.2019 Date Revised 04.12.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1871525716666180313121954 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM281891613 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM281891613 | ||
| 003 | DE-627 | ||
| 005 | 20231225032655.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1871525716666180313121954 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0939.xml |
| 035 | |a (DE-627)NLM281891613 | ||
| 035 | |a (NLM)29532764 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Khalil, Peter |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Entresto, a New Panacea for Heart Failure? |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.02.2019 | ||
| 500 | |a Date Revised 04.12.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.org. | ||
| 520 | |a Heart Failure (HF) is one of the main healthcare burdens in the United States and in the world. Many drugs are approved and used in practice for management of this condition; including beta blockers, diuretics, aldosterone antagonists, Angiotensin Converting Enzyme Inhibitors (ACEI's), and Angiotensin Receptor Blockers (ARBs). Recently, the Food and Drug Administration (FDA) approved a drug with brand name Entresto (Sacubitril/Valsartan or LCZ696), an angiotensin receptor neprilysin inhibitor for the use in Heart Failure with Reduced Ejection Fraction (HFrEF) patients instead of ACEI's and ARBs. The drug works through angiotensin receptor blockage via valsartan as well as neprilysin inhibition with sacubitril. This represented a new milestone in managing heart failure patients and provided yet another therapy in our armamentarium. This article reviews the stages that led to the development of this drug, the failure of its preceding agents, the lessons we have learnt, and the current trials of Entresto for new indications | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Heart failure | |
| 650 | 4 | |a angiotensin receptor blockers | |
| 650 | 4 | |a angiotensin receptor neprilysininhibitor | |
| 650 | 4 | |a angiotensin-converting enzyme inhibitors | |
| 650 | 4 | |a heart failure with preserved ejection fraction | |
| 650 | 4 | |a heart failure with reduced ejection fraction. | |
| 650 | 7 | |a Aminobutyrates |2 NLM | |
| 650 | 7 | |a Angiotensin Receptor Antagonists |2 NLM | |
| 650 | 7 | |a Biphenyl Compounds |2 NLM | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 650 | 7 | |a Tetrazoles |2 NLM | |
| 650 | 7 | |a Valsartan |2 NLM | |
| 650 | 7 | |a 80M03YXJ7I |2 NLM | |
| 650 | 7 | |a sacubitril and valsartan sodium hydrate drug combination |2 NLM | |
| 650 | 7 | |a WB8FT61183 |2 NLM | |
| 700 | 1 | |a Kabbach, Ghazal |e verfasserin |4 aut | |
| 700 | 1 | |a Said, Sarmad |e verfasserin |4 aut | |
| 700 | 1 | |a Mukherjee, Debabrata |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cardiovascular & hematological agents in medicinal chemistry |d 2006 |g 16(2018), 1 vom: 01., Seite 5-11 |w (DE-627)NLM161201482 |x 1875-6182 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2018 |g number:1 |g day:01 |g pages:5-11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1871525716666180313121954 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2018 |e 1 |b 01 |h 5-11 | ||